Search results for "Intestin"

showing 10 items of 2215 documents

The duodenum in liver cirrhosis: endoscopic, morphological and clinical findings.

1991

Endoscopic studies were performed to determine whether changes occurred in the duodenum related to portal hypertension in patients with liver cirrhosis. The total of 271 patients studied were subdivided into three groups: 83 patients with liver cirrhosis and portal hypertension, 53 with liver cirrhosis but no portal hypertension, and 135 controls. In the duodenum of cirrhotic patients with portal hypertension several changes were observed on endoscopy that were also present in the other two groups. Atrophy and vascular malformations, however, were present only in the duodenum of cirrhotic patients with portal hypertension, although in only a few patients and with statistical significance on…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisDuodenumGastroenterologyAtrophyEsophageal varicesDuodenitisInternal medicineHypertension PortalmedicineHumansEndoscopy Digestive SystemIntestinal MucosaAgedmedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseEndoscopymedicine.anatomical_structureDuodenumPortal hypertensionBlood VesselsFemaleComplicationbusinessEndoscopy
researchProduct

Impact of antithrombin III on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis

2005

AIM: To analyze the hepatic and intestinal microcirculation in an animal model of liver cirrhosis and inflammatory bowel disease (IBD) and to characterize the anti-inflammatory action of antithrombin III (ATIII) on leukocyte kinetics and liver damage. METHODS: Hepatic and intestinal microcirculation was investigated by intravital videomicroscopy. Standardized models of experimental chronic liver cirrhosis and bowel inflammation were employed. Animals were divided into four groups (n = 6/group): controls, animals with cirrhosis, animals with cirrhosis and IBD, animals with cirrhosis and IBD treated with ATIII. RESULTS: Cirrhosis facilitated leukocyte rolling and sticking in hepatic sinusoids…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSerine Proteinase InhibitorsAntithrombin IIIInflammationInflammatory bowel diseaseGastroenterologyMicrocirculationEnteritisInternal medicineMedicineAnimalsRats WistarLiver injurybusiness.industryMicrocirculationAntithrombinGastroenterologyGeneral MedicineBlood flowmedicine.diseasedigestive system diseasesEnteritisRatsIntestinesLiverBrief Reportsmedicine.symptombusinessmedicine.drug
researchProduct

TIPS for Prevention of Recurrent Bleeding in Patients with Cirrhosis: Meta-analysis of Randomized Clinical Trials

1999

To compare the effects of transjugular intrahepatic portosystemic shunt (TIPS) creation with those of endoscopic treatment with or without propranolol administration (i.e, conventional treatment) on recurrent bleeding, encephalopathy, and mortality by using meta-analysis of 11 published randomized clinical trials.Data from 11 relevant studies were retrieved by means of computerized and manual search. The combinability of the studies was assessed in terms of clinical and statistical criteria. Data were extracted on the basis of the intention-to-treat principle, and treatment effects were measured as risk differences between TIPS creation and conventional treatment. Pooled estimates were comp…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentEncephalopathyEsophageal and Gastric Variceslaw.inventionRandomized controlled trialRecurrenceRisk FactorslawSclerotherapymedicineSclerotherapyHumansRadiology Nuclear Medicine and imagingbusiness.industryLiver DiseasesHemostasis EndoscopicMiddle Agedmedicine.diseaseSurgeryHepatic EncephalopathyMeta-analysisPortal hypertensionFemalePortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhageVaricesbusinessTransjugular intrahepatic portosystemic shuntRadiology
researchProduct

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

1998

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and…

Liver CirrhosisMalemedicine.medical_specialtyRandomizationmedicine.medical_treatmentAdrenergic beta-AntagonistsOctreotidePlaceboOctreotideHemostaticsPlacebosDouble-Blind MethodMelenaRecurrenceSclerotherapymedicineSclerotherapyHumansHepatologybusiness.industryHematemesisLength of StayMiddle AgedSurgeryClinical trialSurvival RateTreatment OutcomeChemoprophylaxisFemaleComplicationVaricesbusinessGastrointestinal Hemorrhagemedicine.drugHepatology (Baltimore, Md.)
researchProduct

Prognostic indicators of successful endoscopic sclerotherapy for prevention of rebleeding from oesophageal varices in cirrhosis: a long-term cohort s…

2000

Abstract Background. Although band ligation is now recommended for prevention of rebleeding from oesophageal varices in cirrhosis, sclerotherapy is still widely used. Patients submitted to chronic sclerotherapy undergo several endoscopies and experience a large number of serious complications. However, long-term outcome is poorly defined. Aims. To assess the clinical course and prognostic indicators of patients undergoing chronic sclerotherapy for prevention of variceal rebleeding as a basis for future evaluation of long-term band ligation outcome. Methods. Prospective cohort study prognostic analysis by the Cox proportional hazards model. Results. A total of 218 consecutive cirrhotic patie…

Liver CirrhosisMalemedicine.medical_specialtymedicine.medical_treatmentEsophageal and Gastric VaricesGastroenterologyStatistics NonparametricCohort StudiesInternal medicineSclerotherapySecondary PreventionmedicineSclerotherapyHumansesophageal varices liver cirrhosis cohort studyProspective StudiesProspective cohort studySurvival rateAgedHepatologyProportional hazards modelbusiness.industryGastroenterologyMiddle AgedGastric varicesPrognosismedicine.diseaseSurgerySurvival RateTreatment OutcomeFemaleEsophagoscopyGastrointestinal HemorrhageVaricesComplicationbusinessFollow-Up StudiesCohort studyDigestive and Liver Disease
researchProduct

Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients.

2015

The objective of this paper was to validate a previously developed semi physiological model to simulate bioequivalence trials of drug products. The aim of the model was to ascertain whether the measurement of the metabolite concentration-time profiles would provide any additional information in bioequivalence studies (Fernandez-Teruel et al., 2009a,b; Navarro-Fontestad et al., 2010). The semi-physiological model implemented in NONMEM VI was used to simulate caffeine and its main metabolite plasma levels using caffeine parameters from bibliography. Data from 3 bioequivalence studies in healthy subjects at 3 different doses (100, 175 and 400mg of caffeine) and one study in cirrhotic patients …

Liver CirrhosisMetabolitePopulationPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalIntestinal absorptionchemistry.chemical_compoundPharmacokineticsCaffeineMedicineHumansComputer SimulationeducationBiotransformationParaxanthineeducation.field_of_studyDose-Response Relationship Drugbusiness.industryReproducibility of ResultsHealthy VolunteersNONMEMchemistryIntestinal AbsorptionTherapeutic EquivalencyCentral Nervous System StimulantsCaffeinebusinessAlgorithmsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Color Doppler Ultrasound in Portal Hypertension

2020

Portal hypertension is one of the most important causes of morbidity and mortality in cirrhotic patients. A color Doppler evaluation of the left gastric vein (LGV) has proven utility in the prediction of esophageal varices and variceal bleeding in patients with portal hypertension. The purpose of this review is to discuss the ultrasound evaluation, imaging findings, and clinical application of Doppler ultrasound in the assessment of the LGV. Knowledge of the color Doppler technique and imaging findings of the LGV may help clinicians improve the monitoring of portal hypertension and predict patients with a high risk of esophageal varices.

Liver Cirrhosisesophageal varicemedicine.medical_specialtyleft gastric veinLeft gastric veinHemodynamicsEsophageal and Gastric Varicesurologic and male genital diseasesChronic liver disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalHumansMedicineRadiology Nuclear Medicine and imagingUltrasonography Doppler Color030219 obstetrics & reproductive medicineRadiological and Ultrasound TechnologyPortal Veinultrasoundbusiness.industryUltrasoundHemodynamicschronic liver diseaseportal hypertensionColor doppler ultrasoundColor dopplermedicine.diseasefemale genital diseases and pregnancy complicationsPortal hypertensionRadiologycolor DopplerGastrointestinal HemorrhagebusinessJournal of Ultrasound in Medicine
researchProduct

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensate…

2021

[Background & Aims] Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaNASH; cACLD; prognostic factor; steatohepatitis[SDV]Life Sciences [q-bio]cACLD; NASH; Prognostic Factor; Steatohepatitis; Gastrointestinal Hemorrhage; Humans; Liver; Liver Cirrhosis; Retrospective Studies; Carcinoma Hepatocellular; Elasticity Imaging Techniques; Esophageal and Gastric Varices; Liver Neoplasms; Non-alcoholic Fatty Liver Disease610 Medicine & healthEsophageal and Gastric VaricesChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInterquartile rangeInternal medicineAscitesNonalcoholic fatty liver diseasemedicineHumansComputingMilieux_MISCELLANEOUSRetrospective StudiesSteatohepatitisHepatologybusiness.industryPrognostic FactorsteatohepatitiCarcinomaLiver NeoplasmsHazard ratioGastroenterologyNASHHepatocellularcACLDmedicine.disease3. Good healthLiver030220 oncology & carcinogenesisHepatocellular carcinomaElasticity Imaging Techniques030211 gastroenterology & hepatologySteatohepatitismedicine.symptomGastrointestinal HemorrhageTransient elastographybusiness
researchProduct

Prevention of upper gastrointestinal bleeding from portal hypertension in cirrhosis: rationale for medical treatment.

1992

We updated meta-analysis and critical descriptive analysis of randomized clinical trials (RCTs) assessing the value of beta-blockers in preventing first bleeding (prophylactic) or rebleeding (therapeutic) and on survival of patients with cirrhosis. Both the methods of Peto-Mantel-Haenszel and DerSimonian-Laird were used to assess the heterogeneity and obtain cumulative estimates of treatment effects; the L'Abbé plot was also used for a visual assessment of heterogeneity in the direction of treatment effect. Seven prophylactic and nine therapeutic RCTs were analysed. beta-Blockers uniformly reduced the bleeding risk and revealed a trend toward improved survival in non-ascitic, well-compensat…

Liver Cirrhosismedicine.medical_specialtyCirrhosisAdrenergic beta-AntagonistsEsophageal and Gastric Variceslaw.inventionRandomized controlled triallawRecurrenceHypertension PortalMedicineHumansIntensive care medicineMedical treatmentbusiness.industryIncidenceGastroenterologyHemodynamicsGeneral Medicinemedicine.diseaseSurgeryMeta-analysisPortal hypertensionUpper gastrointestinal bleedingbusinessGastrointestinal HemorrhageDigestive diseases (Basel, Switzerland)
researchProduct

Prescription rates of common medications in patients with decompensated cirrhosis in Germany

2021

Adequate pharmacological treatment is of pivotal importance to improve prognosis in patients with decompensated liver cirrhosis. We studied the adherence to recommended pharmacological treatments as secondary prevention in cirrhotic patients following a first decompensation in German primary care.Using the Disease Analyzer Database, the current study sample included patients with liver cirrhosis who had an initial diagnosis of a first decompensation event between 2015 and 2018 (index date) and a follow-up time of at least 6 months after the index date. Pharmacological treatments following the 6 months after the index date were studied.The study included 1538 patients with a first decompensa…

Liver Cirrhosismedicine.medical_specialtyCirrhosisEsophageal and Gastric Variceschemistry.chemical_compoundSpontaneous bacterial peritonitisInternal medicineAscitesmedicineHumansDecompensationMedical prescriptionHepatic encephalopathybusiness.industryGastroenterologyAscitesHepatologymedicine.diseaseRifaximinPrescriptionsPharmaceutical PreparationschemistryHepatic Encephalopathymedicine.symptomGastrointestinal HemorrhagebusinessZeitschrift für Gastroenterologie
researchProduct